Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4293135 | Journal of the American College of Surgeons | 2013 | 12 Pages |
Abstract
Neither RECIST nor mRECIST were predictive of residual viable burden, although the linear trend for mRECIST and residual necrosis + fibrosis compared favorably with RECIST. Continued evaluation for tumor enhancement and standardization of tumor size remain a critical unmet need in patients with solid organ disease.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
Michael E. MD, Robert M. MD, MS, Tiffany L. BS, Michael MD, Larry MD, Cliff MD, Charles R. MD, MBA, FACS, Glenda G. MD, FACS, Kelly M. MD, PhD, FACS, Robert C.G. MD, PhD, FACS,